News

Yahoo Finance1mon
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical ... or other factors; our ability to leverage and enhance our drug discovery platform; our ability ...
Morningstar1mon
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq ... or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing ...
WSPA2mon
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq ... or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing ...
Indiatimes4mon
Reticulated python: Physical characteristics, diet, habitat, and its ability to swallow humans
This is a process that can take a number of hours. Reticulated python: Conservation and human interaction The reticulated python is listed as a species of least concern by the International Union ...
KRON4 News6mon
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Recursion identified the novel regulatory role of RBM39 on CDK12 function using its AI-powered ... enriched cancers but also a testament to our ability to rapidly translate novel insights into ...
Stockhouse7mon
Recursion and Exscientia Shareholders Approve the Proposed Combination
validation of the rationale for the proposed combination and the ability for the combined business to accelerate the discovery of better drugs for patients; the outlook for Recursion’s ...
Nasdaq7mon
Recursion and Exscientia Shareholders Approve the Proposed Combination
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across ...
Stockhouse7mon
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler SALT LAKE CITY, Nov. 12, 2024 (GLOBE ...
Seeking Alpha11mon
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
Recursion’s ability to leverage and enhance its drug discovery platform; Recursion’s ability to obtain financing for development activities and other corporate purposes; the success of ...
KELOLAND News12mon
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
We look forward to highlighting the various aspects of the Recursion value proposition at Download Day.” The event will feature a number of prominent ... % success on our ability to predict ...
Seeking Alpha1y
Recursion to Participate in Upcoming Investor Conferences
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse ...